Superluminal Medicines

Boston GPCR small-molecule company pairing structural biology with ML; Lilly-partnered, MC4R lead heading to Phase 1.

1. Core Product / Service

Superluminal designs small molecules against G protein-coupled receptors (GPCRs). It describes its engine as a "predict-design-test" architecture [1]. Its listed capabilities are structural biology, GPCR co-folding models, de novo small-molecule design, predictive ADME and toxicology models, GPCR biophysics, and what it calls "Agentic Cryo-EM" [3]. The company frames its focus as studying receptors "in a dynamic sense", meaning modeling the multiple shapes a receptor takes rather than one static structure [2].

The lead program is a selective, biased MC4R agonist for rare genetic obesity and hypothalamic obesity. A Phase 1 trial is planned to start by end-2026, with possible later expansion into Prader-Willi syndrome and combination with GLP-1 drugs [3]. At its Series A the company said it had six small-molecule programs [2].

Wet lab. Coverage of the Lilly deal places the headquarters inside Lilly Gateway Labs in Boston, Lilly's incubator that rents lab benches to startups [4]. A 2024 Form D lists a Waltham address [6]. A job posting seeks a scientist to "lead GPCR protein engineering and production" [5], which implies the company makes its receptor proteins in-house. Whether the cryo-EM capability uses owned instruments or outside facilities is not disclosed. Headcount, lab area and CRO partners are also undisclosed.

2. Target Users & Pain Points

• Patients: rare obesity syndromes driven by defects in the MC4R pathway, a pathway already validated by an approved drug, setmelanotide.
• Partners: Eli Lilly, which is a shareholder, a collaborator and, through Gateway Labs, the company's landlord [4].
• Pain addressed: GPCR drugs that are selective for one subtype or biased toward one signaling route are hard to find with static structures; the company's claim is that dynamic structural models make this tractable.

3. Competitive Landscape

4. Unique Observations

• Founding year. SEC Form D gives 2023 as the year of incorporation, with first seed sales in March 2023 [6]; an investor job board lists 2022. Under the stricter test, it belongs to the 2023-or-later cohort.
• Partnered from early on. About a year after the Series A, Lilly signed a deal worth up to ~$1.3B in total value [4], so pharma money arrived during the seed-to-A stage. That makes it a hybrid platform-plus-pipeline company almost from the start.
• Capital-light lab model. Running inside a pharma incubator while building cryo-EM-plus-ML capabilities is the lean end of AI-biotech wet-lab models. The heavy end is the dedicated buildings of xaira-therapeutics or iambic-therapeutics.

5. Financials / Funding

• Total: ~$213M announced [1][2][3].
• Lilly collaboration (2025-08): GPCR targets in cardiometabolic disease and obesity; upfront, equity, milestones and royalties of up to ~$1.3B [4].

6. People & Relationships

• Co-founder & CEO: Cony D'Cruz. Co-founder, Head of Discovery: Ajay Yekkirala [1].
• Other leaders at launch: Yang-Ming Zhu (engineering), Yamina Berchiche (biology), Marek Orzechowski (computational chemistry) [1].
• Investors: RA Capital, Insight, nvidia, Catalio, Eli Lilly, BVF.
• Peers: iambic-therapeutics, genesis-molecular-ai, isomorphic-labs; obesity peers include kailera-therapeutics.

Sources

• [1] Superluminal seed press release via BioSpace (2023-08-28; accessed 2026-10-14)
• [2] Fierce Biotech, "Lilly-backed Superluminal raises $120M series A" (2024-09; accessed 2026-10-14)
• [3] Pulse 2.0, Superluminal $60M Series B led by BVF (2026-09-05; accessed 2026-10-14)
• [4] BioXconomy, "Superluminal and Lilly's $1.3bn pact" (2025-08; accessed 2026-10-14); Investors Hangout summary of the Lilly deal
• [5] Superluminal job posting, GPCR protein engineering (accessed 2026-10-14)
• [6] SEC Form D filings, CIK 1989478 (2023-08 to 2026-09; accessed 2026-10-14)